Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

On the political front, Robert F. Kennedy Jr. will become the next HHS secretary after he attained a majority of Senate votes ...

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

despite a mid-stage stroke trial miss – as well as Anthos Therapeutics with abelacimab, an injectable Factor XI/XIa-targeting antibody that generated encouraging results in a phase 2b trial ...

as well as Anthos Therapeutics with abelacimab, an injectable Factor XI/XIa-targeting antibody that generated encouraging results in a phase 2b trial earlier this year. Milvexian is in three late ...

GLP-1 drugs dominate the obesity market, but Aardvark Therapeutics aims to curb appetite by going after a different target: TAS2 receptors in the gut. The biotech’s lead drug candidate is in ...

After hours: February 20 at 6:58:27 PM EST Loading Chart for NKTR ...

After hours: February 20 at 6:16:04 PM EST Loading Chart for PTIX ...